At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 108 enrolled
Drug / intervention
Risankizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Plaque Psoriasis: Usability of the Risankizumab Autoinjector Combination Product in Adults With Moderate to Severe Psoriasis
In Brief
A Phase 3 clinical trial evaluating Risankizumab and Autoinjector for Psoriasis. Completed, enrolled 108 participants across 26 sites.
Detailed Summary
The objectives of this study were to evaluate the usability of the combination product of risankizumab in an autoinjector (AI), as well as to evaluate the efficacy, safety, and tolerability of risankizumab administered by AI for the treatment of adult participants with moderate to severe plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedMar 2019
Enrollment StartJun 2019
Primary CompletionApr 2020
Study CompletionAug 2020
TodayJul 2026
First PostedMar 14, 2019
Enrollment StartJun 4, 2019
Primary CompletionApr 24, 2020
Study CompletionAug 25, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.3 years ago
Interventions
Risankizumabdrug
Risankizumab to be injected subcutaneously (SC)
Autoinjectordevice
Single dose pre-filled autoinjector containing risankizumab for SC injection